VEGFA and acute respiratory distress syndrome: Some studies suggest that the administration of PRIP-VEGF, which prevents the proteolytic degradation of VEGF, may play distinct yet pivotal roles in mediating inflammation in ARDS, representing a potential novel therapeutic approach for acute and chronic inflammatory pulmonary disease [28].